Science Explorer Back to mapMap
Discussion
Institution · Meridian Clinical Research

Most cited papers from Meridian Clinical Research

Meridian Clinical Research

What are the most cited papers from Meridian Clinical Research?

The most cited paper from Meridian Clinical Research is "Clinical Update: Cardiovascular Disease in Diabetes Mellitus" (Cecilia C. Low Wang, Connie Ng Hess, William Robert Hiatt et al., 2016), with 1,169 citations. Next come "Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants" (1,003) and "A Bivalent Omicron-Containing Booster Vaccine against Covid-19" (659).

Showing 50 of 60 papers. Every paper with more than 34 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Clinical Update: Cardiovascular Disease in Diabetes Mellitus Cecilia C. Low Wang, Connie Ng Hess, William Robert Hiatt et al. · Circulation Open access 13 Jun 2016 1,169
2 Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants Beate Kampmann et al. · New England Journal of Medicine Open access 5 Apr 2023 1,003
3 A Bivalent Omicron-Containing Booster Vaccine against Covid-19 Spyros Chalkias, Charles Harper, Keith W. Vrbicky et al. · New England Journal of Medicine Open access 16 Sep 2022 659
4 Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population Mark R. Nehler, Sue Duval, Lihong Diao et al. · Journal of Vascular Surgery Open access 10 May 2014 504
5 Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants Shabir Ahmed Madhi et al. · New England Journal of Medicine Open access 29 Jul 2020 439
6 Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia J. J. F. Belch, William R. Hiatt, Iris Baumgärtner et al. · The Lancet Open access 30 May 2011 343
7 Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility Paul Bradley, Michael Shiekh, Vishaal Mehra et al. · Journal of Psychiatric Research Open access 23 Sep 2017 227
8 Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years Brandon J. Essink, Charu Sabharwal, Kevin P. Cannon et al. · Clinical Infectious Diseases Open access 22 Dec 2021 178
9 The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials Brandon J. Essink, Laurence Chu, William Seger et al. · The Lancet Infectious Diseases 19 Jan 2023 151
10 Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial Spyros Chalkias, Frank S. Eder, Brandon J. Essink et al. · Nature Medicine Open access 6 Oct 2022 144
11 Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) Warren H. Capell, Marc P. Bonaca, Mark R. Nehler et al. · American Heart Journal 3 Feb 2018 132
12 Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial Isabel Leroux‐Roels et al. · The Journal of Infectious Diseases Open access 29 Jul 2022 124
13 Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study Paul Goepfert et al. · The Lancet Infectious Diseases Open access 20 Apr 2021 123
14 Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis Ivan T. Lee, Raffael Nachbagauer, David J. Ensz et al. · Nature Communications Open access 19 Jun 2023 116
15 Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization Connie Ng Hess, Robert Kevin Rogers, Tracy Y. Wang et al. · Journal of the American College of Cardiology Open access Aug 2018 116
16 Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial Laurence Chu, Keith W. Vrbicky, David C. Montefiori et al. · Nature Medicine Open access 3 Mar 2022 106
17 Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism Neil A. Goldenberg et al. · JAMA Open access 11 Jan 2022 100
18 Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease Cecilia C. Low Wang, Juuso Blomster, Gretchen Heizer et al. · Journal of the American College of Cardiology Open access Dec 2018 97
19 Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization Connie Ng Hess, Tracy Y. Wang, Julia Weleski Fu et al. · Journal of the American College of Cardiology Open access Feb 2020 96
20 Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults Allison August, Christine A. Shaw, Heather Ruth Lee et al. · Open Forum Infectious Diseases Open access May 2022 88
21 Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant John J. Treanor, Brandon J. Essink, Steven G. Hull et al. · Vaccine 27 Sep 2013 87
22 A polygenic risk score predicts atrial fibrillation in cardiovascular disease Nicholas Marston, Amanda C. Garfinkel, Frederick Kamanu et al. · European Heart Journal Open access 18 Aug 2022 85
23 PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes Connie Ng Hess, Cecilia C. Low Wang, William R. Hiatt · Annual Review of Medicine Review 2 Nov 2017 83
24 Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results Spyros Chalkias et al. · Nature Medicine Open access 31 Aug 2023 81
25 Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines Spyros Chalkias, Nichole McGhee, Jordan L. Whatley et al. · medRxiv PreprintOpen access 24 Aug 2023 79
26 Synbiotics‐supplemented amino acid‐based formula supports adequate growth in cow's milk allergic infants A. Wesley Burks, Lucien F. Harthoorn, Marleen T. J. van Ampting et al. · Pediatric Allergy and Immunology Open access 3 Apr 2015 71
27 Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings Neil A. Goldenberg et al. · Journal of Thrombosis and Haemostasis Open access 28 Jun 2015 67
28 Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial Carlos A. Fierro, Daniel C. Brune, Marian Shaw et al. · The Journal of Infectious Diseases Open access 11 Mar 2024 66
29 Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines Spyros Chalkias, Nichole McGhee, Jordan L Whatley et al. · The Journal of Infectious Diseases Open access 13 Feb 2024 64
30 Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study Saranya Sridhar et al. · The Lancet Infectious Diseases Open access 25 Jan 2022 63
31 Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge Lindsey Robert Baden et al. · New England Journal of Medicine Open access 3 Nov 2021 63
32 Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Alex C. Spyropoulos, Walter Ageno, Gregory W. Albers et al. · Journal of the American College of Cardiology Open access Jun 2020 63
33 Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial Rupert Martin Bauersachs, Michael J. Szarek, Marianne Brodmann et al. · Journal of the American College of Cardiology Open access 16 May 2021 56
34 Definition of post‐thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations Neil A. Goldenberg, Leonardo Rodrigues Brandão, Janna M. Journeycake et al. · Journal of Thrombosis and Haemostasis Open access 15 Dec 2011 56
35 Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents Germán Áñez et al. · JAMA Network Open Open access472 authors 26 Apr 2023 54
36 Community-based walking exercise for peripheral artery disease: An exploratory pilot study Ryan J. Mays, William R. Hiatt, Ivan P. Casserly et al. · Vascular Medicine Open access 9 Mar 2015 54
37 Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial Jintanat Ananworanich, Ivan T. Lee, David J. Ensz et al. · The Journal of Infectious Diseases Open access 25 Jun 2024 53
38 Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease Connie Ng Hess, Christopher Paul Cannon, Joshua A. Beckman et al. · Journal of the American College of Cardiology Open access Jun 2021 52
39 Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events Bertram Pitt et al. · JACC Heart Failure Open access Aug 2023 50
40 Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine James T. Peterson, Agnieszka Zareba, David Fitzpatrick et al. · The Journal of Infectious Diseases Open access 11 Oct 2021 50
41 Comparison of the quantification of acetaminophen in plasma, cerebrospinal fluid and dried blood spots using high-performance liquid chromatography–tandem mass spectrometry Rachel R. Taylor, Keith L. Hoffman, Björn Schniedewind et al. · Journal of Pharmaceutical and Biomedical Analysis Open access 17 Apr 2013 50
42 Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial Gregory G. Schwartz, Michael J. Szarek, Deepak L. Bhatt et al. · European Heart Journal Open access 5 Mar 2023 47
43 Community walking programs for treatment of peripheral artery disease Ryan J. Mays, Robert Kevin Rogers, William R. Hiatt et al. · Journal of Vascular Surgery Open access 5 Oct 2013 47
44 Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials Nicholas Marston, James P. Pirruccello, Giorgio E. M. Melloni et al. · Nature Medicine Open access 6 Aug 2024 46
45 Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults Brandon J. Essink, Carlos A. Fierro, Jeffrey Bruce Rosen et al. · Vaccine Open access 18 Oct 2019 45
46 Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study Hayley S. Hancock, Michael Wang, Katja M. Gist et al. · Cardiology in the Young 22 Oct 2012 45
47 Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study Warren H. Capell, Elliot S. Barnathan, Gregory Piazza et al. · American Heart Journal Open access 9 Feb 2021 44
48 Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice Kamlesh K. Khunti, Serge A Jabbour, Xavier Cos et al. · Diabetes Obesity and Metabolism Open access 3 Mar 2022 43
49 Alirocumab after acute coronary syndrome in patients with a history of heart failure Harvey Douglas White, Gregory G. Schwartz, Michael J. Szarek et al. · European Heart Journal Open access 10 Nov 2021 42
50 Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction Tzu‐Fei Wang, Alok A. Khorana, Giancarlo Agnelli et al. · The Oncologist Open access 12 May 2023 40

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.